Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

VelaDx Signs Agreement with Life Technologies to Develop IVD Tests on Ion PGM Sequencer

Published: Wednesday, October 10, 2012
Last Updated: Wednesday, October 10, 2012
Bookmark and Share
Semiconductor sequencing brings unprecedented power to diagnostic tests to transform personalized medicine.

Vela Diagnostics to leverage fast-selling Ion PGM Sequencer to capture untapped global market for fast, simple, affordable sequencing-based diagnostics.

Life Technologies Corporation and VelaDx have entered into a license and supply agreement that will give VelaDx rights to develop and market next generation sequencing-based, in vitro diagnostic tests on the Ion Personal Genome Machine™ (PGM™) platform.  VelaDx will seek approvals from global regulatory authorities for clinical diagnostic tests in oncology and infectious disease.

Vela Diagnostics chose the Ion PGM™ System because of its speed, simplicity and flexibility, and because it's complementary to Vela's Sentosa™ workflow and its menu of qPCR assay kits. Both Ion's PGM™ and Vela's Sentosa™ systems can operate on a menu of single-indication tests or multiple-indication panels that can easily be implemented in virtually any laboratory. A seamless, bi-directional data communication with laboratory information systems between the Ion PGM™ and Sentosa™ systems will maintain the accuracy of data and improve the efficiency of the laboratory workflow.

"Our agreement with Life Technologies puts Vela Diagnostics at the cutting edge position in medicine," said Vela CEO, Michael Tillmann. "The Ion PGM™ System will support Vela's strategy to improve laboratory efficiency and bring new innovative tests to our customers to help improve treatment decisions for patients."

Target markets addressed by VelaDx are attractive and growing quickly.

A recent PiperJaffray report estimates the current infectious disease market to be  $2 billion annually and growing by more than 8 percent.  United Health Group predicts the genetic testing market will grow to $25 billion by 2021.

"Semiconductor sequencing is a transformative technology that can make diagnostic tests faster — a one-day turnaround — and more informative, helping doctors around the world save lives and make personalized medicine a reality," said Ion Torrent President and COO Gregg Fergus. "The founders and management team at Vela Diagnostics have a proven track record of first-mover success in the diagnostic marketplace and are ideal partners to introduce tests in the important clinical areas they have licensed."

The Ion PGM™ Sequencer uses a completely novel sequencing technology that directly translates the language of chemistry into the binary language of computers on a semiconductor chip. This new approach has democratized sequencing, making it far more accessible than ever before. The system can perform a sequencing run in just 90 minutes and automated sample prep makes it easy for a lab technician of any experience level to operate. The cost of the Ion PGM™ System is just a fraction of other systems and accuracy is at a Q30 quality level, both of which are helping to rapidly drive adoption. More than 1,000 units were sold in the system's first 18 months on the market.  Life Technologies plans to seek clearance for the Ion PGM System from the FDA as well as approval from other global regulatory agencies."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FBI Approves Life Technologies' Forensics Kit
Ability to upload forensic samples to National DNA Index System using GlobalFiler DNA chemistry enables faster, more powerful data comparisons to solve crimes in the U.S. and globally.
Tuesday, June 24, 2014
Distribution Agreement to Offer GlobalFiler Express Chemistry
Life Technologies today announced it has signed an agreement giving IntegenX Inc. the rights to distribute its GlobalFiler Express chemistry on IntegenX’s RapidHIT™ platform.
Wednesday, February 26, 2014
Life Technologies' Ion AmpliSeq™ Exome Program Adds 12 New Members
With more than 30 members the program is the largest network of next generation-based exome sequencing providers in the world.
Friday, December 20, 2013
Life Tech's Food Pathogen Detection Methods Approved by Australian Government
MicroSEQ Real-Time PCR workflows approved as method for testing Australian export meat and meat products.
Tuesday, December 17, 2013
KACST Partners with Life Tech in The Saudi Human Genome Program
Program aims to analyze 100,000 human genomes to identify the causes of disease in the population of the Kingdom of Saudi Arabia and the Arab world.
Monday, December 09, 2013
Life Technologies Awards Digital PCR Innovation Grants to Five Research Labs
The five Innovation Grant recipients in the Digital PCR Applications Grant Program was announced during the ASHG conference in Boston.
Thursday, October 24, 2013
BGI Partners with Life Technologies
World's largest genome center to purchase 50 Ion Proton™ Sequencers from Life Technologies.
Tuesday, October 22, 2013
Life Technologies Extends Partnership with DNAVEC
R&D collaborative agreement aims to further develop Sendai virus-based tools for basic and translational research.
Monday, October 21, 2013
Life Tech's Forensic Kit Approved by FBI
Life Technologies GlobalFiler™ Express Kit has been approved by the FBI for use by laboratories generating DNA profiles for inclusion in the National DNA Index System CODIS Database.
Friday, October 11, 2013
Life Technologies Expand Ion AmpliSeq™ Exome Certified Service Provider Program
Due to increased demand the program is expanding to include eleven new members.
Wednesday, October 09, 2013
TriCore Reference Laboratories Named First NGS Center of Excellence by Life Technologies
Collaborative partnership designed to accelerate clinical research in the Southwest using advanced NGS oncology panels.
Thursday, September 19, 2013
Thermo Acquisition Approved by Life Technologies Stockholders
Company announced that its stockholders voted to adopt the previously announced merger agreement.
Thursday, August 22, 2013
Life Technologies Enters into an Exclusive License and Supply Agreement for Dynabead
Life Technologies has signed a long-term supply and exclusive licensing agreement with Novartis for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer.
Thursday, August 01, 2013
Life Technologies Announces Second Quarter 2013 Results
Revenue increased 1% excluding impact of currency.
Thursday, August 01, 2013
Life Technologies Opens State-of-the-Art DNA Forensics Laboratory in India
The new Life Forensics Laboratory will provide much needed high-throughput DNA profiling services in India to help accelerate the sampling process, while saving time and money.
Thursday, August 01, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!